Vanadate and rapamycin synergistically enhance insulin-stimulated glucose uptake

Area of Science:

• Metabolic Regulation
• Cellular Signaling
• Pharmacology

Background:

• Insulin resistance involves negative regulation of insulin action via insulin receptor substrates (IRSs).
• Tyrosine dephosphorylation, serine phosphorylation, and proteasomal degradation of IRSs contribute to this resistance.
• Targeting these pathways may improve insulin sensitivity.

Purpose of the Study:

• To investigate the synergistic effect of inhibiting IRS-1 tyrosine dephosphorylation and proteasomal degradation on insulin-responsive glucose uptake.
• To explore the combined impact of vanadium (a protein-tyrosine phosphatase inhibitor) and rapamycin (an mTOR inhibitor) on glucose transport.
• To elucidate the underlying mechanisms involving IRS-1 phosphorylation, mass, and PI 3-kinase activity.

Main Methods:

• L6 skeletal muscle cells were treated with inhibitors of protein-tyrosine phosphatases (sodium orthovanadate), proteasomal degradation (MG-132), and mTOR (rapamycin).
• Effects of insulin on glucose uptake, IRS-1 tyrosine phosphorylation, PI 3-kinase activity, and IRS-1 mass were assessed.
• Synergistic effects of vanadyl sulfate and rapamycin on insulin-induced glucose uptake were evaluated.

Main Results:

• Simultaneous inhibition of IRS-1 dephosphorylation and degradation synergistically increased insulin-responsive glucose uptake.
• Pretreatment with sodium orthovanadate and rapamycin led to a 5-fold increase in glucose uptake.
• Vanadium and rapamycin blocked IRS-1 mass loss and IRS-1/PI-3 kinase complex decay, enhancing PI 3-kinase activity.

Conclusions:

• Vanadium and rapamycin synergize to enhance glucose uptake by preserving IRS-1 integrity and PI 3-kinase activity.
• This combination therapy prevents IRS-1 mass loss and IRS-1/PI-3 kinase complex decay.
• These findings suggest a novel therapeutic strategy for improving glucose transport in diabetes.